Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis ; volume:23 ; number:1 ; day:16 ; month:5 ; year:2023 ; pages:1-13 ; date:12.2023
BMC cancer ; 23, Heft 1 (16.5.2023), 1-13, 12.2023
- Creator
-
Lin, Chi-Maw
Chang, Lih-Chyun
Shau, Wen-Yi
Chen, Chi-Ling
Yao, Chi-Yuan
Tien, Feng-Ming
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-10907-1
- URN
-
urn:nbn:de:101:1-2023090812564989609327
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T11:02:55+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lin, Chi-Maw
- Chang, Lih-Chyun
- Shau, Wen-Yi
- Chen, Chi-Ling
- Yao, Chi-Yuan
- Tien, Feng-Ming
- SpringerLink (Online service)
Other Objects (12)
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma